Symbols

VTRS

Viatris·NASDAQ

--(--)

VTRS fundamentals

VTRS Q4 2025 Earnings

Viatris (VTRS) released its earnings on Feb 26, 2026: revenue was 3.70B (YoY +4.97%), beat estimates; EPS was 0.57 (YoY +5.56%), beat estimates.

Revenue / YoY

3.70B

+4.97%

EPS / YoY

0.57

+5.56%

Report date

Feb 26, 2026

VTRS Earnings Call Summary for Q4,2025

Sustainable Growth Path: 2026 guided for 2% revenue and EBITDA growth, with $650 million gross cost savings over 3 years to support margin expansion.
Pipeline Momentum: 6 potential approvals in 2026, including Japan launches of Effexor and Pitolisant, and U.S. meloxicam filing.
Free Cash Flow Strength: $2.2 billion in 2025, with $1 billion returned to shareholders, reinforcing financial flexibility.
Strategic Focus: Base business stabilization, innovative portfolio expansion, and modernization to drive mid-single-digit growth by 2028.

Earnings

EPS

Revenue

Revenue & Expenses

VTRS has released its 2025 Q4 earnings report, with revenue of 3.70B, reflecting a YoY change of 4.97%, and net profit of -340.10M, showing a YoY change of 34.15%. The Sankey diagram below clearly presents VTRS's revenue sources and cost distribution.

Key Indicators

Viatris (VTRS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Viatris (VTRS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Viatris (VTRS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Viatris (VTRS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown